| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6100306 | Journal of Crohn's and Colitis | 2012 | 9 Pages |
Abstract
⺠We assess the cost-effectiveness of infliximab and adalimumab for chrohn's disease. ⺠A 5 year probabilistic Markov model used. ⺠Adalimumab costs $193,305 per quality adjusted life year (QALY)versus to usual care. ⺠Infliximab costs $451,165 per QALY compared to adalimumab. ⺠Infliximab and adalimumabmay be poor value for money for Chron's disease.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Gord Blackhouse, Nazila Assasi, Feng Xie, John Marshall, E. Jan Irvine, Kathryn Gaebel, Kaitryn Campbell, Rob Hopkins, Daria O'Reilly, Jean-Eric Tarride, Ron Goeree,